Timber Pharmaceuticals

Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded in 2019 and is headquartered in Basking Ridge, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2023

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trex Wind-down, Inc. engages in the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibroma in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded on August 30, 2010 and is headquartered in Warren, NJ.

- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference -

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis

Virtual Conference on January 10-13, 2022

Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

The stock price of Timber Pharmaceuticals Inc (NYSEAMERICAN: TMBR) increased by over 9% during intraday trading today. This is why it happened.

Timber Pharmaceuticals (TMBR) Stock: Why The Price Jumped Today

Call to be held on Monday, November 22nd at 10:00am ET

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Rais e of $17.25 Million   Announced Subsequent to Quarter End

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million

Timber Pharmaceuticals Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock

Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the closing of its previously announced underwritten public offering of 23,437,500 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 23,437,500 shares of common stock. Each share of common stock (or common stock equivalent) was sold together with one warrant to purchase one share of common stock at a combined public offering price of $0.64 per share of common stock and accompanying common warrant, less underwriting discounts and commissions. The warrants have an exercise price of $0.70 per share, are exercisable immediately, and will expire five years following the date of issuance.

Timber Pharmaceuticals Announces Closing of $15 Million Public Offering

The stock price of Timber Pharmaceuticals Inc (NYSEAMERICAN: TMBR) fell by over 33% during intraday trading today. This is why it happened.

TMBR Stock: Why The Price Plummeted Today

Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the pricing of its previously announced underwritten public offering of 23,437,500 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 23,437,500 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $0.64 per share of common stock and accompanying common warrant, less underwriting discounts and commissions. The warrants have an exercise price of $0.70 per share, are exercisable immediately, and will expire five years following the date of issuance.

Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering

Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock (or common stock equivalents). Each share of common stock (or common stock equivalent) will be sold with a warrant to purchase one share of common stock. The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock (or common stock equivalents) and warrants to be sold in the offering are to be offered by Timber. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Timber Pharmaceuticals Announces Proposed Public Offering

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced positive top-line data from its Phase 2b CONTROL study evaluating TMB-001, an investigational topical isotretinoin formulated using Timber's patented IPEG™ delivery system, in patients with moderate to severe congenital ichthyosis (CI).

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021.

Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

- Topline results expected to be announced in the fourth quarter of 2021 -

Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Genius Brands

Hive Blockchain Technologies Ltd

ObsEva

Ring Energy

SNDL Inc.

Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.

7 Hottest Penny Stocks to Pick Up Now

BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021.

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results

American Battery Technology Company

Citius Pharmaceuticals

Nokia

Transocean

If we've learned anything from the Reddit in January, it's not to underestimate them. These 7 Reddit penny stocks have good upsides.

7 Reddit Penny Stocks to Watch for Big Upside Ahead

Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 3, 2021 its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was convened without a quorum. As a result, in order to provide stockholders additional time within which to vote their eligible shares to establish a quorum, the Annual Meeting was adjourned.

Timber Pharmaceuticals Announces Adjournment of Annual Meeting

Timber Pharmaceuticals Inc (NYSE: TMBR) has completed enrollment in the Phase 2b CONTROL study evaluating TMB-001, a topical pharmaceutical composition of isotretinoin, for moderate to severe subtypes of congenital ichthyosis (CI). The company said that based on the positive safety and efficacy data from unblinded Phase 2a program and feedback from investigators, it would end enrollment early with 35 subjects compared to the planned 45 subjects.

Timber Pharma Shares Jump As Mid-Stage Skin Disorder Study With TMB-001 Concludes Enrollment Early

- Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 -

Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis

Obalon Therapeutics

TETRA Technologies

Before investing in penny stocks, take a look at these 3 things The post Investing in Penny Stocks? Don't Before You Do These 3 Things appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Investing in Penny Stocks? Don't Before You Do These 3 Things

BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021.

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results

- Edward J. Sitar appointed as Lead Independent Director of the Board -

Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors

180 Life Sciences 

Jaguar Health

Ocugen, Inc.

Savara

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Bonanza Creek Energy

Discovery Communications

Riot Blockchain

HighPoint Resources

Ontrak

Reddit stocks continue to have the public's attention. These 7 could be the next short squeeze targets based on technical signs.

DISCB and 6 Other Reddit Stocks Waiting for a Short Squeeze

Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”).  The Company has established April 12, 2021 as the record date for the Annual Meeting.

Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

News for Timber Pharmaceuticals Stock (TMBR)